MLchartDataset catalogue

Ojjaara

Term · Oncology and biomedicine · MLC-T-ONC-006037

A drug used to treat intermediate-risk or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF, in adults with anemia. Ojjaara blocks JAK and other proteins, which may help keep abnormal blood cells or cancer cells from growing. It is a type of kinase inhibitor. Also called momelotinib dihydrochloride monohydrate.

Table 1. Record
IdentifierMLC-T-ONC-006037
FieldOncology and biomedicine
Synonymsmomelotinib dihydrochloride monohydrate
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-006037",
  "term": "Ojjaara",
  "field": "Oncology and biomedicine",
  "definition": "A drug used to treat intermediate-risk or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF, in adults with anemia. Ojjaara blocks JAK and other proteins, which may help keep abnormal blood cells or cancer cells from growing. It is a type of kinase inhibitor. Also called momelotinib dihydrochloride monohydrate.",
  "synonyms": [
    "momelotinib dihydrochloride monohydrate"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/ojjaara/"
}

Record 12,123 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.